Morgan Stanley’s Verrica Pharmaceuticals VRCA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$118K Buy
22,386
+377
+2% +$2.41K ﹤0.01% 6086
2025
Q4
$183K Buy
22,009
+321
+1% +$1.78K ﹤0.01% 5962
2025
Q3
$93.5K Buy
21,688
+19,061
+726% +$115K ﹤0.01% 6185
2025
Q2
$13.9K Sell
2,627
-4,315
-62% -$23.2K ﹤0.01% 6770
2025
Q1
$30.7K Sell
6,942
-29,237
-81% -$189K ﹤0.01% 6431
2024
Q4
$253K Buy
36,179
+18,001
+99% +$198K ﹤0.01% 5701
2024
Q3
$264K Buy
18,178
+9,684
+114% +$436K ﹤0.01% 5648
2024
Q2
$619K Sell
8,494
-4,928
-37% -$379K ﹤0.01% 5191
2024
Q1
$795K Sell
13,422
-8,839
-40% -$488K ﹤0.01% 5090
2023
Q4
$1.63M Buy
22,261
+10,363
+87% +$426K ﹤0.01% 5036
2023
Q3
$462K Buy
11,898
+7,130
+150% +$362K ﹤0.01% 5200
2023
Q2
$275K Sell
4,768
-11,671
-71% -$709K ﹤0.01% 5501
2023
Q1
$1.07M Buy
16,439
+15,113
+1,140% +$914K ﹤0.01% 4813
2022
Q4
$36.5K Sell
1,326
-2,910
-69% -$77.7K ﹤0.01% 6426
2022
Q3
$123K Sell
4,236
-5,173
-55% -$177K ﹤0.01% 5976
2022
Q2
$181K Sell
9,409
-68,762
-88% -$3.46M ﹤0.01% 5953
2022
Q1
$6.34M Sell
78,171
-12,928
-14% -$1.07M ﹤0.01% 3424
2021
Q4
$8.35M Buy
91,099
+86,641
+1,943% +$9.81M ﹤0.01% 3142
2021
Q3
$556K Sell
4,458
-7,749
-63% -$869K ﹤0.01% 5426
2021
Q2
$1.38M Buy
12,207
+11,745
+2,542% +$1.42M ﹤0.01% 4896
2021
Q1
$70K Sell
462
-905
-66% -$125K ﹤0.01% 6195
2020
Q4
$157K Buy
1,367
+806
+144% +$74.1K ﹤0.01% 5713
2020
Q3
$43K Sell
561
-281
-33% -$23K ﹤0.01% 5775
2020
Q2
$93K Buy
842
+288
+52% +$33.3K ﹤0.01% 5439
2020
Q1
$61K Sell
554
-1,631
-75% -$215K ﹤0.01% 5390
2019
Q4
$347K Buy
2,185
+1,793
+457% +$265K ﹤0.01% 5133
2019
Q3
$58K Buy
392
+333
+564% +$37.1K ﹤0.01% 5661
2019
Q2
$7K Sell
59
-174
-75% -$16.3K ﹤0.01% 6239
2019
Q1
$25K Sell
233
-1,382
-86% -$159K ﹤0.01% 5943
2018
Q4
$132K Buy
1,615
+495
+44% +$60.1K ﹤0.01% 5441
2018
Q3
$182K Buy
1,120
+879
+365% +$150K ﹤0.01% 5498
2018
Q2
$47K Buy
+241
New +$47.2K ﹤0.01% 5929

Other funds holding VRCA